Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
UBS
McKinsey
Teva
Argus Health
Citi
Queensland Health
Cantor Fitzgerald
Healthtrust

Generated: November 13, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022255

« Back to Dashboard

NDA 022255 describes VIMPAT, which is a drug marketed by Ucb Inc and is included in three NDAs. It is available from two suppliers. There is one patent protecting this drug and three Paragraph IV challenges. Additional details are available on the VIMPAT profile page.

The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 022255
Tradename:VIMPAT
Applicant:Ucb Inc
Ingredient:lacosamide
Patents:1
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022255
Generic Entry Date for 022255*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022255
Suppliers and Packaging for NDA: 022255
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIMPAT lacosamide SOLUTION;ORAL 022255 NDA UCB, Inc. 0131-5410 0131-5410-70 465 mL in 1 BOTTLE, PLASTIC (0131-5410-70)
VIMPAT lacosamide SOLUTION;ORAL 022255 NDA UCB, Inc. 0131-5410 0131-5410-71 200 mL in 1 BOTTLE, PLASTIC (0131-5410-71)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength10MG/ML
Approval Date:Apr 20, 2010TE:RLD:Yes
Regulatory Exclusivity Expiration:Nov 3, 2020
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:➤ Try a Free TrialPatent Expiration:Mar 17, 2022Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
Patent:➤ Try a Free TrialPatent Expiration:Mar 17, 2022Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Dow
Harvard Business School
Accenture
Cipla
Daiichi Sankyo
McKesson
QuintilesIMS
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.